Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 4/20 | 0.33 |
| ▸ | JAK2 | O60674 | 12/20 | 0.33 |
| ▸ | JAK3 | P52333 | 12/20 | 0.33 |
| ▸ | JAK1 | P23458 | 11/20 | 0.33 |
| ▸ | TYK2 | P29597 | 4/20 | 0.33 |
| ▸ | ALKBH5 | Q6P6C2 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9918449 | 0.80 | JAK2 (0.46) | JAK2JAK3JAK1TYK2 | |
| SCHEMBL9918450 | 0.79 | JAK3 (0.46) | JAK2JAK3JAK1TYK2 | |
| SCHEMBL12832702 | 0.77 | JAK3 (0.46) | JAK2JAK3JAK1TYK2 | |
| SCHEMBL12833308 | 0.74 | JAK3 (0.59) | JAK2JAK3JAK1TYK2 | |
| SCHEMBL9918456 | 0.74 | JAK3 (0.59) | JAK2JAK3JAK1TYK2 | |
| SCHEMBL9918462 | 0.74 | JAK2 (0.47) | JAK2JAK3JAK1TYK2 | |
| SCHEMBL9918452 | 0.73 | JAK3 (0.47) | JAK2JAK3JAK1TYK2 | |
| SCHEMBL9918571 | 0.72 | JAK3 (0.37) | JAK2JAK3JAK1 | |
| SCHEMBL9918570 | 0.71 | JAK3 (0.39) | JAK2JAK3JAK1TYK2 | |
| SCHEMBL9918572 | 0.71 | JAK3 (0.41) | JAK2JAK3JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | FTO 3882/4885JAK2 1/4885JAK3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.